[CAS NO. 146062-46-6] Leriglitazone hydrochloride
PRODUCTS SPECIFICATIONS [146062-46-6]
DESCRIPTION [146062-46-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 408.90 |
| Molecular Formula | C19H21ClN2O4S |
| SMILES | O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(C(O)C)C=C3)C=C2)C1=O.[H]Cl |
Summary
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC 50 of 680 nM [1] .
IC50 & Target
|
PPAR-γ |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05819866 | Minoryx Therapeutics, S.L. |
Cerebral Adrenoleukodystrophy (cALD)
|
July 2023 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL ( 122.28 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4456 mL | 12.2279 mL | 24.4559 mL |
| 5 mM | 0.4891 mL | 2.4456 mL | 4.8912 mL |
| 10 mM | 0.2446 mL | 1.2228 mL | 2.4456 mL |
